Activities
PCSK9 Inhibitors: The Need for a Patient-Centered Approach to Hyperlipidemia Management
0290-0000-21-004-H01-P
This activity highlights an overview of hyperlipidemia and updated guideline recommendations for healthcare professionals as they are intricately involved in identifying appropriate candidates for PCSK9 inhibitor therapy, educating patients, monitoring clinical responses, and working with clinicians to implement crucial interventions.
1.00
PARP Inhibition: Current and Emerging Indications for Use in Ovarian, Breast, Pancreatic, and Prostate Cancers
0290-0000-21-002-H01-P
This webinar will define the role of biomarkers and genetic testing in the selection of patients who may benefit from treatment with a PARP inhibitor.
0.75
HER2-Directed Therapy in Metastatic Breast Cancer: Pharmacist Involvement to Optimize Care
0290-0000-20-404-H01-P
This webinar will prepare pharmacists to identify and manage adverse effects as well as individualize treatment for patients receiving therapies for HER2+ metastatic breast cancer.
0.75
Connecting Biology to Prognosis and Treatment in Non-Hodgkin Lymphoma
0290-0000-20-331-H01-P
This activity will focus on genetic mutations present in various forms of NHL. Additionally, the rationale behind treatment decisions, with an emphasis on national guidelines recommendations, will be discussed.
1.00